|Bid||7.62 x 1800|
|Ask||7.74 x 2200|
|Day's range||7.43 - 8.52|
|52-week range||4.52 - 38.50|
|Beta (5Y monthly)||2.50|
|PE ratio (TTM)||N/A|
|Earnings date||26 Feb 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||28.50|
Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The Company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by our state-of-the-art manufacturing facility in Thousand Oaks, California. For additional information about the Company, please visit atarabio.com.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today provided an update in context of the COVID-19 (coronavirus) pandemic.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Trade deal optimism coupled with the Santa Claus rally have turned the market super bullish for the last five trading days left this year.
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
The South San Francisco, California-based company said it had a loss of $1.44 per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...